MAPS - MAPS

Ultime notizie per WM Tech (NASDAQ:MAPS) Azioni

WM Tech

WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on our marketplace ads.

WM Technology

WM Technology, Inc. - Class A Common Stock

WM Technology Inc

MAPS

HC Wainwright &amp; Co. analyst Edward White maintains Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) with a Buy and raises the price target from $21 to $22.

News

Price Target

Analyst Ratings

AURA

HC Wainwright & Co. Maintains Buy on Aura Biosciences, Raises Price Target to $22

The collaboration supports the licensing of part of Curiosity Stream&#39;s content portfolio in China, Hong Kong, and Macau, bringing 56 unique titles, amounting to 148 hours of premium factual content, to audiences across these territories through various platforms. The deal encompasses a diverse range of programming, from short-form documentary series to premium long-form content.

CURI

Curiosity Inks Strategic Distribution Partnership With Off The Fence; Deal Broadens Company's Footprint Across China, Hong Kong, And Macau

Guidance

CVS's Q3 Results Won't Meet Wall Street's Expectations; Plans To Back Away From Current 2024 Guidance

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

Management

CVS Naming Caremark President David Joyner As Its New CEO

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.

HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

Needham analyst Kyle Peterson reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $350 price target.

Needham Reiterates Buy on Equifax, Maintains $350 Price Target

Needham analyst Mike Matson downgrades Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Buy to Hold and maintains the price target from $86 to $86.

Downgrades

Needham Downgrades Boston Scientific to Hold, Maintains Price Target to $86

WM Technology GAAP EPS of $0.01 misses by $0.01, revenue of $45.9M beats by $2.9M

An announcement from WM Technology (MAPS) is now available. WM Technology, Inc. is experiencing changes in its leadership, with Fiona Tan stepping ...

WM Technology Leadership Changes and Exit Packages

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
WM Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/maps-stock-quote/">MAPS</a>) just reported results for the second quarter of 2024.<ul><li>WM Tech reported earnings per share of 1 cent. This was below the analyst estimate for EPS of 2 cents.</li><li>The company reported revenue of $45.90 million.</li><li>This was 6.75% better than the analyst estimate for revenue of $43.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/maps-stock-earnings-wm-tech-for-q2-of-2024/">MAPS Stock Earnings: WM Tech Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MAPS Stock Earnings: WM Tech Misses EPS, Beats Revenue for Q2 2024

WM Technology, Inc. (MAPS) Q2 2024 Earnings Call Transcript

WM Technology, Inc. 2024 Q2 - Results - Earnings Call Presentation

WM Technology Is Still A Strong Buy

American views on marijuana effects worsening: Gallup

Palantir Technologies (PLTR) delivered robust financial results and expanded operations through strategic partnerships and multi-year contracts in the second quarter. While the company's growing product demand, strategic initiatives, and innovations contribute to its continued growth, the stock is at an elevated valuation. So, let's determine whether Palantir is an ideal addition to your portfolio. Read more to find out... Palantir Technologies Inc. (<a href="https://stocknews.com/stock/PLTR/">PLTR</a>) builds and deploys software platforms for the intelligence community to help with counterterrorism investigations and operations. In the last reported quarter, the company surpassed analyst revenue and earnings expectations. PLTR reported revenue of $678.13 million, topping analysts' estimate of $652.42 million, and its EPS of $0.09, which also surpassed analysts' estimates.
Palantir caters to a wide range of customers, including government and other commercial organizations. During the second quarter, its US government revenue showed growth of 24% year-over-year to $278 million, and its commercial revenue grew 33% year-over-year to $307 million. Also, the company finalized 27 deals worth over $10 million, and its customer count rose 41% year-over-year.
In the recent period, PLTR entered into multiple strategic partnerships with companies, including Microsoft (<a href="https://stocknews.com/stock/MSFT/">MSFT</a>), BP (<a href="https://stocknews.com/stock/BP/">BP</a>), and Tree Energy Solutions, to accelerate their AI-integrated solutions and operations. Also, the company has contracted to provide data integration and AI solutions to drive digital transformation for customers.
PLTR is among the enterprises that have benefitted exponentially from the Artificial Intelligence (AI) revolution. Last year, it launched its Artificial Intelligence Platform (AIP), which has helped the company achieve faster sales growth. Also, with the solid growth trajectory of the Artificial Intelligence market, poised to grow at a <a href="https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-market-74851580.html">CAGR of 35.7%</a> to reach $1.34 trillion by 2030, Palantir's prospects are promising.
However, rising competition and an increasing number of companies engaged in software development and innovations might affect PLTR's market share and current market dominance.
Shares of PLTR have surged 41.3% over the past six months and 123.9% over the past year to close its last trading session at $34.91.
Let's look at factors that could influence PLTR performance in the upcoming months.
Positive Recent Developments
On September 9, PLTR and BP extended their strategic relationship by entering into an enterprise agreement to introduce new artificial intelligence capabilities through Palantir's AIP software. The new contract is built on a decade of deep collaboration that has created a firm foundation for BP's oil and gas production operations using PLTR's industry-leading software.
Through the collaboration, Palantir's AIP software will help BP harness large language models (LLMs) to enhance and accelerate human decision-making with suggested courses of action through automated analysis of the underlying data.
On August 8, PLTR and Microsoft Corporation announced a significant advancement in their partnership to bring sophisticated and secure cloud, AI, and analytics capabilities to the U.S. Defense and Intelligence Community.
This first-of-its-kind integrated technology enables critical national security missions to operationalize Microsoft's best-in-class LLMs through Azure OpenAI (AOAI) Service within PLTR's AI Platform in Microsoft's government and classified cloud environments.
Robust Financials
For the second quarter that ended June 30, 2024, PLTR's revenue increased 27.1% year-over-year to $678.13 million, and its gross profit rose 17.1% year-over-year to $549.57 million. The company's adjusted income from operations of $253.57 million reflects growth of 87.8% from the year-ago value.
In addition, the company's adjusted net income attributable to common stockholders and adjusted EPS came in at $221.41 million and $0.09, up 85.2% and 80% from the prior year's quarter, respectively. PLTR's <a href="https://www.investopedia.com/terms/a/adjusted-ebitda.asp">adjusted EBITDA</a> increased 82.4% year-over-year to $261.62 million.
Also, the company's adjusted free cash flow improved 54.8% from the prior-year quarter to $148.66 million.
Positive Analyst Estimates
Analysts expect PLTR's revenue for the third quarter (ending September 2024) to grow 26.1% year-over-year to $703.69 million. The consensus EPS estimate of $0.09 for the same period reflects a 29.8% year-over-year improvement. Also, it has an impressive earnings surprise history, having topped consensus revenue and EPS estimates in each of the trailing four quarters.
For the fiscal year ending December 2024, the company's revenue and EPS are expected to grow 24% and 42% year-over-year to $2.76 billion and $0.36, respectively. Additionally, Street expects its revenue and EPS for the fiscal year 2025 to increase 20.3% and 21.4% year-over-year to $3.32 billion and $0.43, respectively.
High Profitability
PLTR's trailing-12-month gross profit margin of 81.39% is 64.2% higher than the industry average of 49.58%. Its trailing-12-month net income margin of 16.32% is significantly higher than the industry average of 3.79%. Further, the stock's trailing-12-month EBIT margin of 11.78% is 134.8% higher than the industry average of 5.02%.
Furthermore, the stock's trailing-12-month ROCE, ROTC, and ROTA of 11.55%, 4.75%, and 7.79% are favorable compared to the industry averages of 4.59%, 2.73%, and 2.17%, respectively.
Elevated Valuation
In terms of forward non-GAAP, PLTR is trading at 98.34x, 320.3% higher than the industry average of 23.39x. Likewise, the stock's forward EV/Sales multiple of 27.01 is considerably higher than the industry average of 2.82. Also, its forward EV/EBITDA of 74.47x is 435.2% higher than the industry average of 13.91x.
Also, the stock's forward Price/Sales of 28.34x is significantly higher than the 2.77x industry average. And its Price/Book of 17.60x is 331.1% higher than the industry average of 4.08x.
POWR Ratings Reflect Uncertainty
PLTR's mixed prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of C, which translates to a Neutral in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. PLTR has an A grade for Quality, consistent with its higher-than-industry profitability.
However, the stock received a D grade for Stability, in sync with its 24-month beta of 2.06.
PLTR is ranked #17 in the 18-stock A-rated <a href="https://stocknews.com/category/software-saas/">Software - SaaS</a> industry.
Beyond what is mentioned above, we have also given PLTR grades for Sentiment, Growth, and Momentum. Get access to all the PLTR Ratings <a href="https://stocknews.com/stock/PLTR/">here</a>.
Bottom Line
PLTR's recent strategic innovations and collaborations with industry leaders have strengthened its position in the AI market. Further, with its continuous efforts of leveraging AI for government and commercial contracts have significantly contributed to the operational expansion.
While the company's long-term prospects appear sturdy with strategic partnerships and solid financial performance, its stretched valuation and rising market competition suggest waiting for a better entry point in this stock could be suitable.
Stocks to Consider Instead of Palantir Technologies Inc. (PLTR)
Due to its near-term uncertain prospects, the odds of PLTR outperforming in the weeks and months ahead are compromised. However, there are many industry peers with much more impressive POWR Ratings. So, consider these A (Strong Buy) or B (Buy) stocks from the A-rated <a href="https://stocknews.com/category/software-saas/">Software - SaaS</a> industry instead:
DocuSign Inc. (<a href="https://stocknews.com/stock/DOCU/">DOCU</a>), MiX Telematics Ltd. ADR (<a href="https://stocknews.com/stock/MIXT/">MIXT</a>), and WM Holding Company, LLC (<a href="https://stocknews.com/stock/MAPS/">MAPS</a>).
For exploring more A and B-rated software stocks, <a href="https://stocknews.com/category/software-saas/">click here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
PLTR shares were trading at $35.59 per share on Friday afternoon, up $0.68 (+1.95%). Year-to-date, PLTR has gained 107.28%, versus a 18.99% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/pltr-docu-mixt-maps-msft-bp-does-palantirs-ai-push-make-it-a-buy-now/>Does Palantir's AI Push Make It a Buy Now?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Does Palantir's AI Push Make It a Buy Now?

Trulieve Is Not A Good Cannabis Stock To Own

WM Technology ( ($MAPS) ) has shared an update. Glen Ibbott, with over 25 years of experience, has been appointed to the Board of Directors of WM T...

WM Technology Welcomes New Board Expert, Expands Cannabis Advocacy

AAWH

AYRWF

CBSTF

CNBS

CRLBF

CRON

CURLF

CWBHF

DOCU

ETRGF

FLGC

GLASF

GTBIF

HITI

JUSHF

MAPSW

MIXT

MRMD

MSFT

PCLOF

PLNH

PLTR

SNDL

TCNNF

TLRY

VRNOF

YCBD

YOLO

Press Releases

MAPS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into WM Technology, Inc. and Encourages Investors to Contact the Firm!

Legal

Bragar Eagel & Squire, P.C. Is Investigating WM Technology, Napco, L&W, and Laser Photonics and Encourages Investors to Contact the Firm

Rosen Law Firm Encourages WM Technology, Inc. Investors to Inquire About Securities Class Action Investigation - MAPS

WM Technology, Inc. Announcement: If You Have Suffered Losses in WM Technology, Inc. (NASDAQ: MAPS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages WM Technology, Inc. Investors to Inquire About Securities Class Action Investigation – MAPS

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages WM Technology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MAPS

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of WM Technology, Inc. Investors– MAPS

Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against WM Technology, Inc. f/k/a Silver Spike Acquisition Corp.

Comments

WM Tech

Notizie

Ultime notizie per WM Tech (NASDAQ:MAPS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO